CD8A and neoplasm: In cancer immunotherapy, tumor-derived exosomes (TEX) as potent cell-free peptide-based antitumour vaccine through dendritic cell-released MHC class I/peptide complexes for efficient CD8+ T cell priming to suppress tumour growth or prime naive Tc1 lymphocytes leading to tumor rejection (Andre et al., 2004; Chaput et al., 2004).